COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication

Data de publicação:

Autores da FMUP

  • Tiago Emanuel Azenha Rama

    Autor

  • Diana Margarida Gonçalves Solha Pereira Da Silva

    Autor

  • André Miguel Afonso De Sousa Moreira

    Autor

Participantes de fora da FMUP

  • Miranda, J
  • Amaral, L
  • Castro, E
  • Coimbra, A
  • Placido, JL

Unidades de investigação

Abstract

Reported cases of anaphylaxis following COVID-19 vaccination raised concerns about the safety of these vaccines, namely in patients suffering from clonal mast cell (MC) disorders-a heterogenous group of disorders in which patients may be prone to anaphylaxis caused by vaccination. This study aimed to assess the safety of COVID-19 vaccines in patients with clonal MC disorders. We performed an ambidirectional cohort study with 30 clonal MC disorder patients (n = 26 in the prospective arm and n = 4 in the retrospective arm), that were submitted to COVID-19 vaccination. Among these, 11 (37%) were males, and median age at vaccination date was 41 years (range: 5y to 76y). One patient had prior history of anaphylaxis following vaccination. Those in the prospective arm received a premedication protocol including H1- and H2-antihistamines and montelukast, while those in the retrospective arm did not premedicate. Overall, patients received a total of 81 doses, 73 under premedication and 8 without premedication. No MC activation symptoms were reported. COVID-19 vaccination seems to be safe in patients with clonal mast cell disorders, including those with prior anaphylaxis following vaccination. Robust premedication protocols may allow for vaccination in ambulatory settings.

Dados da publicação

ISSN/ISSNe:
2076-393X, 2076-393X

Vaccines  Multidisciplinary Digital Publishing Institute (MDPI)

Tipo:
Article
Páginas:
718-
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 6

Citações Recebidas na Scopus: 9

Documentos

  • Não há documentos

Filiações mostrar / ocultar

Keywords

  • COVID-19 vaccines; mastocytosis; clonal mast cell activation syndrome; anaphylaxis

Financiamento

Proyectos asociados

Airborne food and aeroallergens levels in healthcare settings. An unaccounted but potentially relevant source of exposure?

Investigador Principal: André Miguel Afonso de Sousa Moreira

Estudo Clínico Académico (Aeroallergens) . 2020

Eosinophil cationic protein (ECP) correlates with eosinophil cell counts in the induced sputum of elite swimmers

Investigador Principal: André Miguel Afonso de Sousa Moreira

Estudo Clínico Académico (ECP) . 2021

How exercise, physical activity and diet modulate immune and stress responses

Investigador Principal: André Miguel Afonso de Sousa Moreira

Estudo Clínico Académico . 2020

Citar a publicação

Partilhar a publicação